GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » Valuation Rank

Microbix Biosystems (TSX:MBX) Valuation Rank


View and export this data going back to 1992. Start your Free Trial

What is Microbix Biosystems Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Microbix Biosystems Valuation Rank Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Microbix Biosystems Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » Valuation Rank
Comparable Companies
XCNQ:DTC TSXV:COV TSXV:SHRX TSXV:MIR TSX:SVA TSXV:NRX TSX:ONC TSX:HBP XCNQ:ONCO TSX:MDNA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
MBXBF:USA
Address
265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Website
https://www.microbix.com
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and; Development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
Executives
James Stuart Currie Senior Officer
Mark Adrian Luscher Senior Officer
Bo Hollas Director
Jennifer Anne Stewart Director
Cameron Lionel Groome Director, Senior Officer
Kenneth Hughes Senior Officer
Martin Marino Director
Peter Martin Blecher Director
Philip Jonathan Casselli Senior Officer
Steven Trevor Hagerman Senior Officer
Damian Klimaszewski Senior Officer
Anthony J. Giovinazzo Director